AOD-9604 Metabolic Research and Lipolysis

Human growth hormone is a 191-amino-acid polypeptide with pleiotropic actions, encompassing both somatogenic (growth-promoting) and lipolytic (fat-metabolizing) activity. Research at Monash University established that these activities reside in structurally distinct regions of the molecule, and that the C-terminal region carries much of the lipolytic signal. AOD-9604 is the synthetic realization of that observation: a 16-residue compound comprising hGH residues 177 through 191 with an additional tyrosine residue at the N-terminus, occupying position 176. It carries a disulfide bridge and a molecular weight of approximately 1817 Da.

The compound was developed by Metabolic Pharmaceuticals as an obesity drug candidate, advancing through preclinical work and into human trials in the 2000s before development was discontinued. It did not receive pharmaceutical approval. The body of published research it generated, however, remains a substantive resource for investigators studying adipocyte metabolism and the structural dissection of growth hormone activity.

The central research premise behind AOD-9604 is receptor selectivity. Intact growth hormone binds the growth hormone receptor, driving hepatic IGF-1 production, cell proliferation, and effects on glucose homeostasis alongside its lipolytic activity. Heffernan and colleagues (2001), publishing in the International Journal of Obesity, used in vitro assays specifically to test whether AOD-9604 acts through this receptor. The research reported that the fragment’s metabolic effects were not mediated through the growth hormone receptor, and that the compound did not induce cell proliferation via that receptor.

This distinguishes AOD-9604 mechanistically from growth hormone secretagogues, which act upstream to raise endogenous growth hormone and consequently IGF-1. For that contrasting mechanism, see our overview of Tesamorelin and growth hormone-releasing hormone research, where GHRH receptor agonism drives the full growth hormone axis rather than isolating a single downstream activity.

Ng and colleagues (2000), publishing in Hormone Research, examined AOD-9604 in obese Zucker rats. Chronic oral administration over 19 days was associated with a reduction of over 50 percent in body weight gain relative to control animals, and adipose tissue from treated animals showed increased lipolytic activity. Notably, euglycemic clamp analysis found no adverse effect on insulin sensitivity, standing in contrast to what the same research group observed with chronic intact hGH treatment.

Extending this into energy-balance measurements, Heffernan and colleagues (2001) reported in the International Journal of Obesity that chronic treatment of obese ob/ob mice with either hGH or AOD-9604 was associated with increased fat oxidation and reduced body weight. These findings positioned the fragment as a research tool for isolating substrate-oxidation effects from the broader endocrine cascade triggered by full-length growth hormone.

AOD-9604’s relationship to the beta-3 adrenergic receptor (beta-3 AR), the principal lipolytic receptor of adipose tissue, is frequently oversimplified. The primary study is Heffernan and colleagues (2001) in Endocrinology, which examined chronic treatment in both obese mice and beta-3 AR knockout mice. The research reported that hGH and AOD-9604 each reduced body weight and body fat in obese mice, and that these outcomes correlated with increased expression of beta-3 AR messenger RNA, restoring the repressed beta-3 AR RNA levels of obese mice toward those seen in lean controls.

In beta-3 AR knockout mice, long-term treatment with either compound failed to reproduce the change in body weight and the increase in lipolysis. Critically, however, in an acute experiment AOD-9604 remained capable of increasing energy expenditure and fat oxidation in those same knockout animals.

The authors’ stated conclusion is therefore precise: the lipolytic actions of hGH and AOD-9604 are not mediated directly through the beta-3 AR, although both compounds increase beta-3 AR expression, which may subsequently contribute to enhanced lipolytic sensitivity. The distinction matters. AOD-9604 is frequently described as a beta-3 AR agonist that binds and activates the receptor. The primary research supports upregulation of receptor expression, not direct receptor agonism, and the compound’s precise molecular target remains uncharacterized.

Beyond adipose metabolism, AOD-9604 has been examined in a connective tissue context. Kwon and Park (2015) investigated ultrasound-guided intra-articular injection of AOD-9604, with and without hyaluronic acid, in a collagenase-induced knee osteoarthritis model in New Zealand white rabbits. The research reported that morphological and histopathological cartilage scores improved relative to saline control, and that the combination of AOD-9604 with hyaluronic acid outperformed either agent administered alone within that model.

This line of inquiry is considerably less developed than the metabolic literature and rests on a small number of animal studies. It is included here for completeness of the published research record rather than as an established property of the compound.

Cox and colleagues (2015), writing in Drug Testing and Analysis, characterized the in vitro metabolism of AOD-9604 in serum and urine, identifying six potential metabolites. Quantification in serum identified a single metabolite consisting of the residues CRSVEGSCG that proved substantially more stable than both the other metabolites and the parent compound. For investigators designing pharmacokinetic or analytical work, this metabolite stability profile is directly relevant to detection windows and assay design.

Researchers should note that AOD-9604 is a compound prohibited by the World Anti-Doping Agency. Any research involving human subjects or athlete populations carries regulatory obligations well beyond the scope of this overview.

Preclinical literature has examined AOD-9604 across several interconnected research contexts: